- Report
- July 2023
- 180 Pages
Global
From €5715EUR$5,950USD£4,920GBP
- Report
- January 2024
- 175 Pages
Global
From €4802EUR$5,000USD£4,134GBP
- Report
- November 2023
- 175 Pages
Global
From €4802EUR$5,000USD£4,134GBP
- Report
- June 2023
- 338 Pages
Global
From €7203EUR$7,500USD£6,202GBP
- Report
- May 2021
- 250 Pages
Global
From €8596EUR$8,950USD£7,401GBP
- Report
- January 2021
- 143 Pages
China, Global
From €3000EUR$3,346USD£2,673GBP
- Report
- January 2023
- 257 Pages
Global
From €3429EUR$3,570USD£2,952GBP
Brinzolamide is a carbonic anhydrase inhibitor used to treat ocular hypertension and glaucoma. It is a topical ophthalmic solution that works by decreasing the amount of fluid in the eye, thereby reducing intraocular pressure. It is often used in combination with other medications to treat glaucoma. Brinzolamide is available in both generic and brand-name formulations. Common side effects include stinging, burning, and redness of the eyes.
Brinzolamide is a key component of the optical disorders drugs market. It is used to treat a variety of ocular conditions, including glaucoma, ocular hypertension, and uveitis. It is also used to reduce the risk of vision loss in patients with glaucoma. Brinzolamide is a cost-effective treatment option for many patients, as it is available in both generic and brand-name formulations.
Some companies in the Brinzolamide market include Alcon, Allergan, Bausch + Lomb, and Santen Pharmaceuticals. Show Less Read more